QDDresearch

Empire Company Limited EMP.A

Consumer StaplesFood & Drug RetailingCanada

Last close 50.27 CAD on Nov 1, 2026, +7.4% year to date

Quant rating

Quant rating A+ Rank 1 of 21 in Consumer Staples
  1. Growth B 13 of 21
  2. Valuation B 9 of 21
  3. Quality B 14 of 21
  4. Revisions A 2 of 21
  5. Momentum B 9 of 21

Wall Street consensus Hold (3.00)Average target 53.50 CAD +6.4%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Growth and profitability fiscal year ends April 30

Growth and profitability by fiscal year
202620252024202320225Y avg
Revenue (mil)31,95031,27730,73330,47830,162–
Revenue growth2.2%1.8%0.8%1.0%6.7%2.5%
EPS (basic, normalized)3.242.982.742.802.80–
EPS growth8.7%8.8%−2.1%0.0%––
Gross margin27.1%26.8%26.3%25.6%25.4%26.2%
Net margin0.6%2.2%2.4%2.3%2.5%2.0%
ROE3.8%13.0%13.8%13.5%15.9%12.0%
Balance sheet, last quarter
Cash & short-term investments (mil)320
Current ratio0.82x
Long-term debt (mil)6,936
Net debt (mil)7,612
Total equity (mil)5,115
Net debt / equity1.49x
Net debt / EBITDA3.04x

Estimates and valuation

Consensus estimates and implied multiples
Sales (mil)EBITDA (mil)EPS
Fiscal yearMean est.GrowthEV/SalesMean est.GrowthEV/EBITDAMean est.GrowthP/E
2026 actual 31,950+2.2%0.4x 2,500+3.6%5.5x 3.24+8.7%15.5x
2027 32,916+3.0%0.4x 2,644+5.8%5.2x 3.59+10.7%14.0x
2028 33,889+3.0%0.4x 2,742+3.7%5.1x 3.87+7.8%13.0x
2029 34,423+1.6%0.4x 2,756+0.5%5.0x 4.06+4.9%12.4x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
SalesEPS
Fiscal yearEstimate (mil)1M3M6MEstimate1M3M6M
202732,916+0.1%−0.1%+0.2%3.59+0.3%−0.2%+0.3%
202833,889+0.2%−0.2%0.0%3.87+0.2%−0.5%−1.2%
202934,4230.0%−1.2%–4.060.0%−3.3%–

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter endedApr 2024Jul 2024Oct 2024Jan 2025Apr 2025Jul 2025Oct 2025Jan 2026Apr 2026Jul 2026
Sales reported (mil)7,4128,1377,7787,7257,6378,2587,9957,8907,8078,475
Sales mean (mil)7,3988,0617,8797,6637,6528,2847,9577,9077,8098,543
Surprise+0.2%+0.9%−1.3%+0.8%−0.2%−0.3%+0.5%−0.2%0.0%−0.8%
EPS reported0.630.900.730.620.740.910.690.720.941.04
EPS mean0.620.880.660.620.710.880.700.710.871.04
Surprise+1.1%+2.1%+10.4%+0.5%+4.2%+3.6%−1.6%+1.4%+7.7%+0.2%

Peer comparison Food & Drug Retailing

Peers in the same industry group, by market capitalization
CompanyMarket capNet debt/EBITDANet marginP/BFY1 P/EFY2 P/EFY1 EV/EBITDAFY2 EV/EBITDA
EMP.A Empire Company Limited6.3B3.04x0.6%2.20x14.0x13.0x5.2x5.1x
L Loblaw Companies Ltd79.5B2.09x4.0%7.28x26.9x24.0x12.6x11.8x
WN George Weston Limited40.2B3.55x1.6%8.91x22.8x19.5x8.7x8.1x
CASY Caseys General Stores Inc35.2B1.29x4.1%6.14x31.8x29.0x16.6x15.3x
MRU METRO INC.20.2B2.36x4.6%2.92x21.3x17.9x12.3x11.0x
MAKSY Marks and Spencer Group PLC16.0B–––13.0x11.9x––
Mean2.47x3.0%5.49x21.6x19.2x11.1x10.3x
Median2.36x4.0%6.14x22.0x18.7x12.3x11.0x

Technical analysis

  • 1M+5.2%
  • 3M−1.9%
  • 1Y+5.2%
  • 3Y+43.9%

Financial statements in millions of CAD

Income statement, Empire Company Limited, fiscal years, most recent first
202620252024202320222021
Total revenue31,95031,27730,73330,47830,16228,268
Cost of revenue23,28622,89522,66222,68522,50321,069
Gross profit8,6648,3828,0707,7937,6607,199
Selling, general & administrative expenses6,8626,6546,3546,1475,9785,508
Research & development––––––
Depreciation/amortization598583564542496443
Interest expense (income), operating−65.0−68.0−51.1−87.7−93.1−51.4
Unusual expense (income)642−61.0−75.1−25.1−68.616.7
Other operating expenses41.0−15.0−32.2−16.1−16.7−15.9
Operating income5861,2891,3111,2321,3641,300
Net interest income (expense)−269−285−273−258−272−259
Gain (loss) on sale of assets––––––
Other non-operating income (expense)−9.0−9.0−9.3−9.2−9.7−10.4
Net income before taxes3089951,0289651,0821,030
Provision for taxes62.0249266238270266
Minority interest−48.0−46.0−37.4−41.7−65.5−62.7
Equity in affiliates––––––
U.S. GAAP adjustment––––––
Net income before extraordinary items198700725686746702
Extraordinary items––––––
Net income198700725686746702
EBIT, normalized1,1631,1721,1851,1201,2021,265
EBITDA, normalized2,3292,2902,2532,1502,1682,109
Basic EPS, normalized3.242.982.742.802.80–

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.